HC Wainwright Cuts Lexaria Bioscience (NASDAQ:LEXX) Price Target to $7.00
Lexaria Bioscience (NASDAQ:LEXX – Free Report) had its price target trimmed by HC Wainwright from $10.00 to $7.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...
HC Wainwright Has Positive View of Precigen FY2024 Earnings
Analysts at HC Wainwright boosted their FY2024 earnings estimates for Precigen in a research report issued to clients and investors on Thursday, January 23rd. HC Wainwright analyst S. Ramakanth now ...
Optimistic Outlook on Larimar Therapeutics’ Nomlabofusp: Advancements in Clinical Trials for Adolescents with Friedreich’s Ataxia
Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on LRMR stock, giving a Buy rating on January 24.Invest with ...
Arcutis Biotherapeutics Receives Buy Rating Amid Strong Prescription Growth in Zoryve Franchise
Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on January 13.Invest with Confidence: ...
Netflix, Palantir And Moderna Are Among Top 12 Large Cap Gainers Last Week (Jan 20-Jan 24): Are The Others In Your Portfolio?
These twelve large-cap stocks were the best performers in the last week. Are they in your portfolio?